Drug development firms already need a little prodding to consider working with their counterparts on the medical device side, especially when it comes to brand new compounds, but they “do see the benefits for next-generation” drugs.

— Simon Bennett, Business Development Director at Glide Pharma (Oxford, UK) discussing how his company is creating its own drug/device product pipeline using generic compounds, while collaborating with partners to develop new compounds with its delivery system, “New drug/device combinations: salvaging dropped compounds,” pp. 1, 7.